Early Detection of Ovarian Precancer via Blood Marker
The level of CA125 is raised in the blood during ovarian cancer. On the horizon of a sometimes late-stage disease, researchers have uncovered a blood marker that can detect changes at the molecular level before an ovarian cancer can grow.
Researchers have been working for decades to identify ovarian cancer at an earlier stage. In the hope of catching smaller tumors, they said in their report Tuesday in Nature Medicine.
Researchers at the Hoag Family Cancer Institute in Newport Beach, California, asked whether they could find the earliest molecular warning signs before invasive cancer develops. The initial symptom of ovarian cancer is usually the presence of tiny abnormalities in the cells that line the fallopian tubes. Serous tubal intraepithelial carcinoma is the name given to the precancerous lesions.
Women who have this precursor condition have higher levels of a molecule of RNA called Tu-Stroma in their blood, the new investigation reported. In blood samples, researchers found STIC in 92.3% of women with the disease and correctly diagnosed 98.2% of women who were not affected by the disease. If the test is positive, the women with genetic risk factors would have about 72% accuracy, and if the test is negative, they would be nearly 100% accurate, they reported.
This may change the way we think about prevention for women at high risk, said Dr. Esha Madan, another Hoag study author.
Targeted Two-Drug Therapy for Bladder Cancer Patients
Many of these women will need to make a challenging decision regarding having preventative surgery to remove their fallopian tubes and their ovaries.
“For the most part, decisions regarding preventive surgery are made based on inherited risk, but there’s no certainty that precancerous lesions exist,” Madan said. “Eventually, the biological information we’ve found could fill in that missing link.”
An alternative to radical cystectomy for patients with bladder cancer who are not eligible for chemotherapy.
In a large clinical trial, a new method appeared to work well for patients with bladder cancer, particularly those who could not have the chemotherapy typically used before surgery to help prevent cancer coming back.
Patients who received AstraZeneca’s (AZN) immunotherapy Imfinzi and the targeted cancer drug Padcev from Astellas Pharma, followed by immunotherapy, had a 42% reduced risk of death compared to patients who had surgery alone, before bladder removal surgery.
Nearly 700 patients were enrolled in the study, which was a randomized trial, and had tumors that had invaded the muscular wall of the bladder. Such tumors typically are treated with chemotherapy to make them smaller before surgery and to minimize the likelihood of their returning.
However, almost half of these patients can’t take the standard chemotherapy drug, cisplatin, and thus have limited treatment options, said Dr. Alexandra Drakaki of the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) in a release.
About 45% of those who got the two-drug therapy did not have detectable cancer in the tissues taken out during surgery, while about 10% of patients who had surgery but no chemotherapy beforehand did not, the researchers wrote in The New England Journal of Medicine.
Three-quarters of those receiving the two-drug therapy survived after two years, compared with 69% of the surgically treated patients.
At two years, about 64% of the medicated group had not had an event related to the cancer vs 45% of the straight-to-surgery group.
Padcev is an antibody-drug conjugate that binds to a protein found on bladder cancer cells and takes a cancer drug directly to them, whereas Imfinzi is a protein that prevents the immune system from detecting cancer cells.
Most patients were able to complete the preoperative treatment, despite a high incidence of severe adverse events, the researchers noted.
How Daily Coffee Consumption Influences Gut Microbes
The results provide a chance for surgeons to recommend a treatment – before surgery – to those muscle-invasive bladder cancer patients who are not eligible for cisplatin, Drakaki explained.
The digestive function of coffee drinkers might be better. Coffee drinkers may be better digesters.
Coffee consumption is known not only to influence the numbers of organisms in the small intestine, but also the digestive tract’s function itself, according to a Danish study.
In this study, as in previous studies, coffee drinkers had a greater diversity of microorganisms in their gut than those who drank coffee less often, researchers noted.
But frequent coffee drinkers also had more contractions in the colon, which can support healthy digestion, help prevent constipation and keep the intestinal muscles in good condition, study leader Francesca Bucci of the University of Copenhagen said in a statement.
Coffee drinkers also had significantly lower pH in the small intestine, researchers reported in Gut Microbiology.
They haven’t yet determined if a lower pH increases or decreases the likelihood of benefiting from a food, but interestingly, pH level is important to how the food breaks down.
Small electronic capsules measuring, among other things, temperature, pH, and gut contractions were swallowed by the 61 study participants to track them through the digestive system.
The study included those who were defined as “frequent coffee drinkers” if they had a cup of coffee at least once a day on at least three of the eight days of the study.
The study cannot prove the differences are due to coffee consumption. Yet there are many processes in the digestive tract that are known to be affected by coffee, including those that involve acid production in the stomach, the researchers note.
“Many people experience constipation and irregular bowel movements,” said study co-author Henrik Munch Roager, of the University of Copenhagen, in a statement.
Understanding the New Ovarian Cancer Blood Test
The new ovarian cancer blood test uses a molecular approach to identify early biological changes associated with cancer development
Instead of looking exclusively for an established tumor, researchers investigated whether blood samples could reveal molecular signals associated with precancerous conditions.
The study identified Tu-Stroma, an RNA molecule that appeared at elevated levels in women with STIC.
This approach could provide researchers with an additional way to identify ovarian cancer risk before invasive disease develops.
Unlike conventional diagnostic approaches that focus on detecting existing tumors, the new research explores the possibility of identifying warning signals at an earlier biological stage.
The new ovarian cancer blood test represents a promising development in early disease detection, offering researchers a new way to identify precancerous changes before invasive ovarian cancer develops. By analyzing the Tu-Stroma RNA biomarker, scientists hope to improve ovarian cancer risk assessment and support earlier medical intervention.
This innovative approach could transform future ovarian cancer research, particularly for women with inherited genetic risk factors. Early identification of ovarian cancer warning signals may help doctors make more informed healthcare decisions. Although the test has demonstrated encouraging results, further studies are needed to establish its reliability for ovarian cancer detection. Researchers believe this technology could improve ovarian cancer prevention strategies and contribute to better outcomes for patients affected by ovarian cancer.


